- Home
- PPLI vs ABCL Comparison
PPLI vs ABCL Comparison
Compare PPLI & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PPLI | ABCL |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.5B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PPLI | ABCL |
|---|---|---|
| Price | $41.24 | $13.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $56.80 | $16.67 |
| AVG Volume (30 Days) | 1.1M | ★ 4.0M |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.97 | 10.91 |
| EPS | ★ 5.65 | N/A |
| Revenue | ★ $4,365,235,000.00 | $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.70 | $12.68 |
| P/E Ratio | $7.25 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $35.38 | $2.75 |
| 52 Week High | $48.32 | $14.98 |
Technical Indicators
Market Signals| Indicator | PPLI | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 61.70 | 73.83 |
| Support Level | $40.37 | $3.39 |
| Resistance Level | $47.96 | N/A |
| Average True Range (ATR) | 1.28 | 0.74 |
| MACD | 0.66 | 0.18 |
| Stochastic Oscillator | 89.99 | 92.13 |
Price Performance
Historical ComparisonAbout PPLI People Incorporated Common Stock
People Inc is a media and publishing business that operates a portfolio of brands, including PEOPLE, Food & Wine, Travel + Leisure, InStyle, Better Homes & Gardens, and Southern Living. The company also holds a minority equity stake in MGM Resorts International.
About ABCL AbCellera Biologics Inc.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.